Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
← catalyst calendarNCT07652294 · readout in 926 d
Sponsored by Spyre Therapeutics, Inc. (industry) · SYRE — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · Triple · Treatment
Enrollment
645estimated
Sites
16
Countries
Czechia, Georgia, Greece +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-08 | actual | When the study began enrolling |
| Primary completion | 2029-03-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-03 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative
Interventions
- Drug: SPY001 — also filed as SPY001-001
- Drug: SPY002 — also filed as SPY002-091
- Drug: SPY003 — also filed as SPY003-207
Primary outcome
what the primary-completion date above is the date OFPercentage of participants who experienced an adverse event
measured Week 96
Permalink · SYRE's whole pipeline · Catalyst calendar · Every registered study · What changed